FDA committee recommends six peptides, includin...
Wednesday, July 29th, 2026 - The U.S. FDA Pharmacy Compounding Advisory Committee has recommended adding six peptide substances, including BPC-157, TB-500, and MOTS-c, to the FDA's 503A Bulks List. This list allows licensed compounding pharmacies to prepare medications using these substances under specific regulations. Vanta Holdings, a longevity-focused health company, supports th
What changed
The source item comes from Pluang, which Medriva treats as news discovery. The practical significance is not that readers should change treatment decisions on their own, but that regulatory, safety, access, or development assumptions may need to be checked against current source language.
Why it matters
President Trump said that he’ll impose a 100% tariff on all generic drugs starting in August 2028–and rising to 200% the following year. Around 90% of prescriptions are filled by generics, which are largely manufactured overseas, where costs to make these inexpensive drugs are cheaper. India, for example, is a major hub of generics manufacturing: nearly half Medriva tracks these items because older summaries can become misleading when supply, enforcement, trial, or safety information changes.
What readers should check
Readers should compare the new source with the relevant Medriva tracker or evergreen page before relying on older assumptions. The item should not be treated as individualized medical advice, a dosing recommendation, or a vendor recommendation.
Related reading
- Peptide Tracker
- Retatrutide profile
- Semaglutide profile
- Tirzepatide profile
- FDA warning letters tracker
- Clinical review methodology
---
Source: Pluang
Disclaimer: For informational and educational purposes only. Not medical advice. Always consult a licensed clinician.
